Conventional therapy of Sjogren's syndrome

Mavragani, CP; Moutsopoulos, HM

dc.contributor.author	Mavragani, CP	en
dc.contributor.author	Moutsopoulos, HM	en
dc.date.accessioned	2014-03-01T11:46:17Z
dc.date.available	2014-03-01T11:46:17Z
dc.date.issued	2007	en
dc.identifier.issn	1080-0549	en
dc.identifier.uri	https://dspace.lib.ntua.gr/xmlui/handle/123456789/37777
dc.subject	Sjogren's syndrome	en
dc.subject	therapy	en
dc.subject	conventional treatment	en
dc.subject	sicca features	en
dc.subject.classification	Allergy	en
dc.subject.classification	Immunology	en
dc.subject.other	NON-HODGKINS-LYMPHOMAS	en
dc.subject.other	DOUBLE-BLIND	en
dc.subject.other	DRY EYE	en
dc.subject.other	RAYNAUDS-PHENOMENON	en
dc.subject.other	FOLLOW-UP	en
dc.subject.other	SALIVARY	en
dc.subject.other	XEROSTOMIA	en
dc.subject.other	RITUXIMAB	en
dc.subject.other	PLACEBO	en
dc.subject.other	TRIAL	en
dc.title	Conventional therapy of Sjogren's syndrome	en
heal.type	other	en
heal.language	English	en
heal.publicationDate	2007	en
heal.abstract	Sjogren's syndrome (SS) is a chronic autoimmune disorder affecting mainly middle-aged women. It is characterized by lymphocytic infiltration and destruction of the exocrine glands (mainly the salivary and lacrimal glands), resulting in dry mouth and eyes. Symptoms of SS are chronic and sometimes devastating, compromising the quality of life at a major extent. Despite its autoimmune nature, evidence for the use of immunosuppressive agents, which are the mainstay of therapy of diseases of autoimmune origin, is limited. Keratoconjunctivitis sicca (KCS), the main ocular manifestation of SS, is managed with tear substitutes, as well as local and systemic stimulators of tear secretion and supportive surgical procedures. Management of oral manifestations includes intense oral hygiene, prevention and treatment of oral infections, use of saliva substitutes, and local and systematic stimulation of salivary secretion. Cholinergic agents, such as pilocarpine and cevimeline are the cornerstone of current therapy in SS. Corticosteroids, cyclophoshamide, and nucleoside analogues are reserved for severe extraglandular manifestations of SS. The role of anti-B-cell therapy is a promising option for glandular and extraglandular manifestations of the disease, as well as for the management of SS-associated lymphoma.	en
heal.publisher	HUMANA PRESS INC	en
heal.journalName	CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY	en
dc.identifier.isi	ISI:000251150600011	en
dc.identifier.volume	32	en
dc.identifier.issue	3	en
dc.identifier.spage	284	en
dc.identifier.epage	291	en